Dr. Kabir Oladipo Olaniran, MD, MPH

Dr. Olaniran practices at UT Southwestern Oakcliff Dialysis in Dallas, Texas.

Dr. Olaniran's NPI, 1447597166, was assigned on January 15, 2013. Dr. Olaniran graduated from University of Lagos College of Medicine in 2006. Dr. Olaniran holds Texas license S0348.

Dr. Olaniran's primary practice is UT Southwestern Oakcliff Dialysis, at 610 Wynnewood Vlg, Dallas, TX 75224 in Dallas County. The practice phone is (469) 895-5907.

Dr. Olaniran's primary practice is UT Southwestern Oakcliff Dialysis in Dallas, Texas. Dr. Olaniran is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Olaniran to 1 more hospital, 1 dialysis center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Olaniran practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Olaniran's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Olaniran is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Olaniran's licenses on file in 2 states: Texas and Massachusetts.

Dmand AI lists acute kidney failure, chronic kidney disease and kidney disease among the conditions Dr. Olaniran treats.

CMS data shows 189 Medicare services from Dr. Olaniran across 5 procedure codes in 2024, for 130 Medicare patients. Medicare paid $29,140 for them.

CMS counts 130 Medicare patients who saw Dr. Olaniran in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 33% are also on Medicaid. Their average risk score is 4.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Olaniran's median patient age at 57, with 50% women.

In 2024, Dr. Olaniran wrote 311 Medicare Part D claims for 77 patients. 78% of them were for generic drugs. CMS names the drug for 180 of them, across 7 drugs with 11 or more claims each, at $36,083 in total drug cost. In 2023, CMS named 89 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Olaniran for performance year 2024, reported as part of a group. Dr. Olaniran accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Olaniran as offering telehealth.

Dmand AI links 15 papers to Dr. Olaniran, published from 2014 to 2024. 2019 was the busiest year, with 4. The most frequent topics are Anemia, Sickle Cell, Black or African American and Sickle Cell Trait. Dr. Olaniran has published most often in Am J Nephrol. Dr. Olaniran's most frequent co-authors are Sagar Uday Nigwekar, MD, Ravi Ishwar Thadhani, MD, MPH and Andrew S. Allegretti, MD.

CMS Open Payments shows 4 general payments to Dr. Olaniran from 1 drug or device company from 2017 to 2019. Travel and lodging make up the largest share, 53% of the total. Fresenius USA Marketing, Inc. paid the most, $1,942.

Dmand AI lists 8 awards for Dr. Olaniran, most recently KL2 Scholar in 2024.

Dr. Olaniran graduated from University of Lagos College of Medicine in 2006. Dr. Olaniran is a member of ASH, ASN and NKF.

Dr. Olaniran is in network with 19 carriers, including Blue Cross Blue Shield of Michigan, Elevance and United Healthcare. HMO plans come from the most carriers, 12. Check the plan with the practice before a visit.